ArticleFrontiers in oncology2025
Case Report: Ablation as novel x therapy in the regimen for frail hematological malignancies with extramedullary lesion.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Exploring the applicability, combined strategies, and challenges of ablation in hematology based on its characteristics and immunomodulatory mechanisms.Clinical and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematological diseases, as a category of malignant tumors originating from the hematopoietic system, have long relied on treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. However, challenges remain in managing locally progressive lesions, relapsed/refractory lesions, and involvement of special anatomical sites, especially in infirmities. Ablation technology, as a minimally invasive local treatment method, directly destroys lesion tissues through physical energy and has been widely used in the field of solid tumors. In recent years, with advancements in image-guided technology and the presence of unmet clinical needs in the local treatment of hematological diseases, studies have begun to explore the application of ablation technology in hematological diseases. We retrospectively analyzed 4 frail hematological malignancies cases to discuss the application significance and indications of local ablation therapy in hematological diseases of frail patients, aiming to provide references for clinical practice.Case 1 and Case 2 involved patients with relapsed/refractory multiple myeloma. Both patients had extramedullary lesions in the left maxillary region and the left tibial anterior area, and were unable to tolerate intensive treatment. Case 3 was diagnosed with diffuse large B-cell lymphoma (DLBCL) combined with large extramedullary lesion masses. Case 4 was diagnosed with DLBCL combined with synovial sarcoma. Case 3 and 4 patients were over 80 years old. The four patients were treated with a combination of local ablation and low-dose systemic chemotherapy. After the treatment, all four patients achieved varying degrees of remission, improvement in local compression symptoms, and enhancement of quality of life, with no obvious side effects. Our study demonstrated for the first time the good safety and efficacy of ablation combined with chemotherapy for frail patients, and also indicated that ablation can be used as a new treatment strategy for elderly frail B-cell malignancies patients with local extramedullary lesions who cannot tolerate intense systemic treatment, or for those B-cell malignancies with multiple relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.